Natural killer cells plus immunotherapy for small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests combining natural killer (NK) cells with an immunotherapy drug as a maintenance treatment after standard chemotherapy for small cell lung cancer that has spread. The goal is to see if this combination can help keep the cancer from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old.
- Have small cell lung cancer that has spread to other parts of the body (extensive stage).
- Completed 4 cycles of platinum chemotherapy plus immunotherapy, and the cancer has not grown (stable, partial, or complete response).
- Be physically active and able to care for yourself (ECOG score 0-2).
- Have adequate organ function (bone marrow, liver, kidneys).
- Not have active brain metastases, autoimmune diseases, or other serious uncontrolled conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two experimental immunotherapy drugs (ivonescimab and cadonilimab) with standard chemotherapy for people with extensive-stage small cell lung cancer who have not had prior treatment. The goal is to see if this combination works better than chemo alone.
This trial tests a combination of chemotherapy, immunotherapy, and targeted radiation for people with extensive-stage small-cell lung cancer. The goal is to see if adding radiation to leftover tumors after initial treatment helps control the disease better.
This trial tests whether adding natural killer (NK) cell therapy to standard chemotherapy and a PD-1 inhibitor (a type of immunotherapy) before surgery can help shrink early-stage non-small cell lung cancer and improve outcomes. The goal is to see if this combination is safe and effective.
This trial tests giving standard chemotherapy and radiation together with two types of immunotherapy (which helps your immune system fight cancer) for limited-stage small cell lung cancer. The goal is to see if adding these immune treatments improves outcomes compared to standard care.
This trial tests a combination of an immunotherapy drug (tislelizumab) with standard chemotherapy (and sometimes radiation) for people with small cell lung cancer that has spread to only a few spots in the body. The goal is to see if adding immunotherapy helps control the cancer better than chemotherapy alone.
This trial tests adding natural killer (NK) cells to your usual maintenance treatment for advanced solid tumors. NK cells are a type of immune cell that may help your body fight cancer more effectively and delay the cancer from growing.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.